It has been reported that splenic stromal cells (SSCs) are capable of directly supporting the development of CD11c lo CD45RB 1 IL-10-producing dendritic cells (DCs) from lineage-negative c-kit 1 progenitor cells in the absence of exogenous cytokines. In vitro, DCs that differentiate on stromal cells suppress mixed leukocyte reaction responses and induce primary alloreactive CD4
INTRODUCTION
Stromal cells, which are key regulators of hematopoiesis, are composed of a heterogeneous cell population; for example, spleen stroma consist of a mixture of fibroblasts and endothelial cells, in addition to some adherent dendritic cells (DCs) and macrophages.
1 Recent studies have consistently suggested that stromal cells play a pivotal role the development of splenic DCs by establishing the cellular microenvironments. [2] [3] [4] [5] It has also been found that splenic stromal cell (SSC) monolayers play an essential role by supporting stem cell maintenance, renewal, and the specific differentiation of only DCs and no other hematopoietic cells. 6 Importantly, extensive in vitro studies have provided compelling evidence that suggests that stromal cells can exert profound immunosuppressive effects via the modulation of both cellular and innate immune pathways. 7, 8 DCs are professional antigen-presenting cells (APCs). 9, 10 These cells play a pivotal role in the induction of the immune response and tolerance depending on their activation state, maturation status and, as recently proposed, the cytokine milieu at sites of inflammation. [11] [12] [13] In cases of transplantation, DCs that present processed donor major histocompatibility complex peptides actively participate in graft rejection by stimulating recipient T-cell responses following organ transplantation. However, it is becoming clear that DCs serve not only as initiators of allograft rejection but also as key arbiters for the induction of allograft tolerance. Therefore, the remarkable functional plasticity of DCs renders them attractive therapeutic targets for immune modulation in transplantation.
It has been reported that DCs generated on stromal cells can induce primary alloreactive CD4
1 T cells to differentiate into IL-10-producing Tr1 cells. 5 Consistent with these observations, more recent studies have indicated that SSCs provide an immune microenvironment that is preferential to the development of regulatory DCs. As a result, mature DCs cultured in the presence of stromal cell monolayers were shown to differentiate into a new subset of DCs with regulatory function. 8 Based on these observations, the goal of the present study was to determine whether infusion of donor-specific SSCs would induce antigen-specific tolerance and, as a result, prevent allograft rejection. For this purpose, we used murine skin and cardiac allograft transplantation as models for the study. We found that infusion of donor-specific SSCs significantly prolonged the survival of murine skin allografts. Our studies further demonstrated that enhanced allograft survival is associated with an increased production of IL-10 and transforming growth factor (TGF)-b and augmented CD4 1 CD25
1 Foxp3 1 regulatory T cells (Tregs). Moreover, we found that IDO and SSC-derived regulatory DCs promote allograft protection by infusion of donor-specific SSCs. Together, our data suggest that donorderived SSCs are a potential therapeutic target for the induction of transplantation tolerance.
MATERIALS AND METHODS
Mice Six-to eight-week-old specific pathogen-free female C57BL/6 (B6) H-2 b , BALB/c H-2 d and C3H H-2 k mice were obtained from the animal facilities at Tongji Medical College (Wuhan, China). All mice were maintained under specific pathogen-free conditions and the studies were carried out in compliance with the institutional animal care and use guidelines.
Reagents and antibodies
Collagenase D, mitomycin C, lipopolysaccharide and IDO inhibitor 1-methyl-DL-tryptophan (1-MT) were obtained from Sigma-Aldrich (Saint Louis, MO, USA). Slow-release polymer pellets containing 1-methyl-tryptophan and empty placebo pellets were purchased from Innovative Research of America (Sarasota, FL, USA). Carboxyfluorescein diacetate succinimidyl ester (CFSE) was purchased from Molecular Probes (Eugene, OR, USA). FITC-labeled antiCD11c (clone HL3), phycoerythrin (PE)-labeled anti-CD11c, APClabeled anti-CD11c (clone HL3), anti-CD16/32 (2.4G2), FITC-labeled anti-CD4 (clone GK1.5), PE-labeled anti-CD25 (clone PC-61), PElabeled anti-CD8a (clone 53-6.7) and control rat IgG were obtained from BD Biosciences (San Diego, CA, USA). PE-conjugated antimouse F4/80 (clone BM8), PE-conjugated rat anti-mouse CD45R/ B220 (clone RA3-6B2), PE-conjugated rat anti-mouse CD45RB (clone C363.16A) and APC-conjugated rat anti-mouse Foxp3 (clone FJK16s) were obtained from eBioscience (San Diego, CA, USA).
SSC preparation
SSCs were prepared as described previously. 15 Briefly, stromal components from BALB/c mice were obtained by perfusion of spleens with RPMI 1640 medium followed by collagenase digestion (0.5 mg/ml) for 45 min at room temperature. The digested tissues were washed twice with RPMI 1640 medium, followed by centrifugation at 20g for 15 min. The pelleted cells were resuspended in complete DMEM medium supplemented with 10% fetal calf serum (Sigma-Aldrich), seeded in 90 mm Petri dishes (Nunc; 10 7 cells/dish) and incubated for 4 h at 37 uC to allow the cells to adhere. The cultures were subsequently washed three times with RPMI 1640 medium to remove any nonadherent cells. After the cells were cultured overnight, the dishes were again washed twice with RPMI 1640 medium to remove any transient non-adherent cells. The remaining monolayer of adherent cells was SSCs.
Flow cytometric analysis
For analysis of DC phenotype and surface marker expression, splenic single-cell suspensions from C57BL/6 mouse recipients after day 7 of transplantation were prepared and incubated with anti-CD16/CD32 monoclonal antibody to block FccR. After being stained with CD11c, the cells were costained for CD8a, CD45R/B220 or anti-CD45RB. DC phenotype and surface marker expression levels were then analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) as previously reported. 17 For analysis of regulatory T cells, splenocytes were isolated from the recipient mice after day 7 of transplantation and subsequently costained with anti-CD4-FITC and anti-CD25-PE. For intracellular analysis of Foxp3 expression, the cells were further stained with either APC-labeled rat anti-Foxp3 or rat IgG2a (as an isotype control) using established techniques. 18 Finally, the cells were subjected to flow cytometric analysis and the collected data were analyzed using CellQuest software (BD Biosciences, Mountain View, CA) as specified by the manufacturer.
Infusion of SSCs, implantation of IDO inhibitor pellet and skin allograft transplantation Prior to day 7 of transplantation, the prospective recipient mice (C57BL/6, n56 per group) were subjected to infusion of 5310 6 BALB/c donor-derived SSCs via the tail vein. Mice subjected to infusion with either 5310 6 BALB/c spleen cells or phosphate-buffered saline (PBS) were included as controls. Full-thickness skin allograft transplantation was performed as previously described. 9 In brief, the recipient mice were anesthetized and the area around the chest and abdomen was shaved. Skins were prepared from the trunk of either BALB/c mice or third-party donors (i.e., C3H mice, as controls). After any subcutaneous fat was removed, 12-mm-diameter circles of fullthickness skin were simultaneously transplanted onto the alternate dorsal thorax of the C57BL/6 recipients. Skin grafts were inspected daily to monitor the survival time until rejection occurred, which was defined as the complete loss of viable epidermal graft tissue characterized by 50% of the graft surface appearing raised and necrotic by visual examination. In selected animals, allograft rejection was further confirmed by histological analysis. To assess the effect of inhibiting recipient IDO, either slow-release polymer pellets containing 1-methyl-tryptophan (6 mg/mouse/day, 12-day release) or placebo pellets were inserted surgically under dorsal skin when skin transplantation was performed.
Skin allograft histology
Histological analysis was performed as previously reported. 19 After day 7 of transplantation, the skin allografts were excised and fixed in 4% paraformaldehyde. Serial sections (5 mm in thickness) were prepared using a microtome and stained with hematoxylin/eosin for the analysis of pathological changes.
Mixed leukocyte reaction
A BALB/c-derived T-cell proliferation assay was performed in the presence or absence of BALB/c-derived SSCs using mitomycin Ctreated splenocytes isolated from C57BL/6 mice as stimulators. T-cell proliferation was assessed by serial dilution of the intracellular CFSE dye as described previously. 20 In brief, stimulator cells were prepared from the splenocytes of C57BL/6 mice and were treated with mitomycin C (40 mg/ml, 37 uC for 1 h), while BALB/c-derived responder T cells were purified using nylon wool columns and further stained with CFSE. The cells were then placed in a 24-well round-bottom plate; each well contained both 2310 6 responder cells and 4310 5 stimulator cells. The mixed cells were cultured for 5 days at 37 uC with 5% CO 2 in the presence or absence of a monolayer of SSCs before being harvested for flow cytometric analysis of CFSE-positive cells. To assess the regulatory role of IDO expressed by SSCs, the IDO inhibitor 1-MT was added to the cell culture system at a final concentration of 200 mM.
Quantitative RT-PCR analysis Total RNA was isolated from either SSCs or recipient spleens after day 7 of transplantation using the acid guanidium phenol-chloroform method. 21 Ten micrograms of RNA was used for cDNA synthesis using a Moloney murine leukemia virus reverse transcriptase kit (Fermentas Life Sciences, St Leon-Rot, Germany). The relative expression levels of each selected cytokine were determined by quantitative Figure 3 Intravenous infusion of SSCs prolongs the survival of skin allografts and attenuates the infiltrate of leukocyte into the grafts. (a) C57BL/6 mouse recipients were treated with intravenous infusion of either 5310 6 SSCs from BALB/c mice per mouse or PBS 7 days prior to transplantation; these mice were then transplanted with either BALB/c or third-party C3H skin grafts (n56-8 mice per group). The MST of the grafts was monitored. *P,0.05. (b) Histological analysis of skin allografts after day 7 of transplantation revealed reduced levels of allograft leukocyte infiltration and necrosis in the SSC-treated group compared to that of the PBS or C3H groups (3200). (c) C57BL/6 mouse recipients were treated with intravenous infusion of 5310 6 SSCs from BALB/c mice per mouse 7 days prior to transplantation, and then transplanted with BALB/c skin grafts (n56 mice per group) and implanted with slow-release polymer pellets containing 1-methyl-tryptophan or placebo pellets under the dorsal skin. The MST of the grafts was monitored. *P,0.05. (d) Histology indicated that the allografts in recipients treated with 1-MT exhibited more severe infiltration and necrosis than the implants in recipients that received placebo treatment (3200). The data shown are representative of three independent experiments. MST, mean survival time; 1-MT, 1-methyl-DL-tryptophan; PBS, phosphate-buffered saline; Spl, spleen cell; SSC, splenic stromal cell.
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RT-PCR. The primers used for PCR amplification were as follows: IDO, forward 59-GTA CAT CAC CAT GGC GTA TG-39, reverse 59-GCT TTC GTC AAG TCT TCA TTG-39; TGF-b, forward 59-CTA CTG CTT CAG CTC CAC AG-39, reverse 59-TGC ACT TGC AGG AGC GCA C-39; IL-10, forward 59-ATC GAT TTC TCC CCT GTG-39, reverse 59-AAT GGG AAC TGA GGT ATC AG-39; IL-2, forward 59-ATG AAC TTG GAC CTC TGC-39, reverse 59-TCT CCT CAG AAA GTC CAC CAC-39; and b-actin, forward 59-GCA TCC TCA CCC TGA AGT A-39, reverse 59-TTC TCC TTA ATG TCA CGC AC-39. PCR amplification was performed for 30 cycles consisting of the following steps: 5 min at 94 uC for denaturing, 30 s at the optimal temperatures specific to the primers used for annealing and 30 s at 72 uC for extension. The products were resolved on a 2% agarose gel followed by densitometric analysis using a light imaging system (Peiqing Keji, Shanghai, China). b-actin was used for normalization.
Isolation and infusion of SSC-derived DCs for cardiac allograft transplantation SSC-derived DCs were isolated from BALB/c donor-derived SSCs 7 days after in vitro culture using an EasySep System (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's instructions. In brief, single-cell suspensions of SSCs were first incubated with a species-specific Fc-blocking antibody and a PEconjugated anti-CD11c antibody, followed by positive isolation of DCs using the EasySep selection cocktail and EasySep magnetic nanoparticles target cells that were labeled with PE-conjugated antibodies for magnetic separation. To test the regulatory effects of these SSCderived DCs in vivo, 2310 5 DCs were administered intravenously into naive recipient C57BL/6 mice 7 days prior to BALB/c mouse donor heart transplantation. Heterotopic heart transplantation was performed as previously reported. 19 The pulsation of heart grafts was monitored daily by two independent observers without prior knowledge of the treatment protocol.
Statistical analysis
Allograft survival differences among groups were analyzed using the method of Kaplan and Meier. Comparisons of two means were performed using the unpaired t-test. Regression curves were fitted using SigmaPlot software (version 6.0; SPSS, Chicago, IL, USA). All other data were analyzed by one-way analysis of variance. Statistical significance was defined as P,0.05.
RESULTS

SSCs possess the capability to differentiate into regulatory DCs
We first performed in vitro studies to assess the capability of SSCs to differentiate into DCs. To this end, SSCs were isolated by collagenase digestion and cultured in the conditions described in the section on 'Materials and methods'. We found that some of the SSCs became confluent after 7 days of culture ( Figure 1a) . These confluent cells were collected and subjected to flow cytometric analysis to assess DC and macrophage surface marker expression levels. As expected, roughly 8.860.6 and 11.461.1% of the non-adherent cells were found to be CD11c 1 DCs and macrophages, respectively (Figure 1b, upper and lower panels). We next examined the capacity of SSCs to direct local differentiation of CD11c 1 CD45RB 1 regulatory DCs. For this purpose, we costained these cells with CD11c and CD45RB. Flow cytometric analysis revealed that roughly 20.963.5% of the CD11c 1 DCs also expressed CD45RB (Figure 1c ).
SSCs suppress IDO-dependent alloreactive T-cell proliferation
We next performed studies to determine the capability of SSCs generated by our culture system to suppress alloreactive T-cell responses. Figure 4 DCs from recipients treated with a SSC infusion display a tolerogenic phenotype. Spleen cells from mice treated with a SSC infusion or PBS-treated control mice were analyzed for the expression of CD11c, CD45RB (upper panel), CD8a (middle panel) and B220 (lower panel), 7 days after skin graft transplantation. The value represented in each dot plot is the percentage of the specified DC subset. The data shown are representative of three independent experiments that yielded comparable results. *P,0.05, **P,0.01. DC, dendritic cell; N. S., not significant; PBS, phosphate-buffered saline; Spl, spleen cell; SSC, splenic stromal cell.
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To this end, BALB/c-derived alloreactive T cells were stimulated with mitomycin C-treated C57BL/6 splenocytes in the presence or absence of BALB/c-derived SSCs. Alloreactive T-cell proliferation was then determined by flow cytometric analysis of CFSE-positive cells. As shown in Figure 2a , the addition of SSCs significantly suppressed the proliferation of alloreactive T cells. To assess the possible regulatory role of IDO expressed by SSCs, 200 mM 1-MT was added to cell culture system to inhibit IDO activity. We found that inhibition of IDO significantly decreased the regulatory effect of SSCs on alloreactive T-cell proliferation. RT-PCR analysis revealed that exogenous interferon (IFN)-c upregulates the expression of IDO by SSCs (Figure 2b ).
Infusion of donor-derived SSCs prolongs skin allograft survival
Based on the above results, we next sought to explore the feasibility of using SSCs to induce antigen-specific allograft tolerance in transplantation. For this purpose, 5310 6 SSCs that originated from BALB/c mice were injected into C57BL/6 recipient mice via the tail vein as described in the section on 'Materials and methods'. 7 days after injection, the mice were transplanted with BALB/c-derived skin allografts. Recipient mice injected with either spleen cells or PBS were used as controls. To determine whether the tolerance induced by SSC infusion was antigen-specific, some of the SSC infused BALB/c mice were transplanted with C3H-derived skin allografts. Six mice were included in each study group, and allograft rejection was defined as complete loss of viable epidermal graft tissue. As shown in Figure 3a , the mean graft survival time (MST: 11.362.1 days) for the recipient mice pre-infused with donor-specific SSCs was significantly longer than that of recipients that were pre-injected with PBS (MST: 8.561.0 days, P,0.05) or spleen cells (MST: 9.7561.4 days, P,0.05). Consistent with these observations, histological analysis of the allografts after day 7 of transplantation revealed much more severe inflammatory infiltrations in recipient mice pre-injected with PBS compared to recipients that were preinfused with SSCs (Figure 3b) . These results suggest that pre-infusion of donor-derived SSCs induced tolerance and, as a result, prevented skin allograft rejection.
It is important to note that, unlike the recipient mice implanted with BALB/c-derived skin grafts, the infusion of recipient mice with BALB/c-derived SSCs failed to enhance the survival time of skin allografts that originated from C3H mice. These mice exhibited an MST that was similar to that of recipient mice treated with PBS (MST: 8.760.6 days versus 8.561.0 days; Figure 3a ). Histological analysis of these allografts after day 7 of transplantation revealed very strong allograft infiltration and necrosis that was similar to that observed in recipient mice pre-treated with PBS ( Figure 3b ). Taken together, our results suggest that infusion of donor-derived SSCs prevents allograft rejection by inducing antigen-specific tolerance. 
CD25
1 T cells was analyzed by intracellular staining. The values presented in the dot plot represent the percentages of the specified T-cell subsets. The data shown are representative of three independent experiments that yielded comparable results. *P,0.05, **P,0.01. PBS, phosphate-buffered saline; SSC, splenic stromal cell.
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IDO plays an essential role in SSC-mediated allograft protection
Because we have previously demonstrated that IDO plays a role in allograft tolerance, 17, 19 we tested whether IDO is essential for the protection of skin allografts by infusion of donor-derived SSCs. To this end, we inhibited IDO in the SSC-treated recipients with slowrelease polymer pellets containing 1-MT; mice that received placebo pellets served as negative controls. As shown in Figure 3c , the in vivo inhibition of IDO resulted in a shorter skin allograft survival time (MST: 960.58 days) in the recipients with SSC infusion compared to mice from the placebo groups (MST: 11.860.91 days, P,0.05). Allografts in the recipients treated with 1-MT exhibited severe infiltration and necrosis (Figure 3d) . These results indicate that IDO plays an essential role in SSC-mediated allograft protection.
Infusion of donor-derived SSCs induces tolerogenic DCs in the recipient mice
To elucidate the possible mechanisms underlying SSC-induced tolerance, we first examined the DC phenotype of the recipient mice. Splenic DCs were prepared from both SSC-treated and control mice and were subsequently subjected to flow cytometric analysis to assess surface marker expression levels. We observed a slight increase in the number of CD11c 1 CD45RB 1 DCs in SSC-treated mice in comparison with that in control mice (6.5260.35% versus 5.0860.28%, P50.037; Figure 4 , upper panel). Interestingly, a significantly higher proportion of splenic CD8a
1 DCs was observed in SSC-treated recipient mice compared to that in the PBS-treated control mice (0.9560.07% versus 0.6260.01%, P,0.05; Figure 4 , middle panel). Notably, we did not observe a significant difference between spleen cell-and SSCs-treated animals in terms of the proportion of splenic CD8a 1 DCs (P.0.05). Similarly, a significant increase for plasmacytoid DCs (pDC) was also observed (3.0560.19% versus 1.1360.07%, P,0.01; Figure 4 , lower panel). Since CD8a 1 DCs and pDCs also have regulatory functions, 15 our data suggest that infusion of donorderived SSCs induced an increase in the number of regulatory DCs in the recipient mice.
Donor-derived SSCs enhance Treg production in recipient mice
Given the importance of regulatory DCs in the induction of regulatory T cells, we next evaluated the differences between Tregs isolated from the recipient mice. To this end, splenic T cells isolated from each group of recipient mice were stained for intracellular Foxp3 after costaining to assess surface CD4 and CD25 expression and subsequently subjected to flow cytometric analysis. Recipient mice pre-infused with donor-specific SSCs exhibited significantly higher numbers of CD4 1 CD25 1 Foxp3 1 Tregs than PBS-treated control recipients (5.1661.6% versus 2.7861.8%, P,0.05; Figure 5 ).
Infusion of SSCs enhances recipient splenocyte IL-10 and TGF-b expression
We next tested whether infusion of donor-specific SCCs affects the cytokine expression profiles of recipient splenocytes. To assess changes in the expression profiles, RNA was isolated from each group of recipient mice and subsequently used for quantitative RT-PCR analysis of cytokine expression levels. We observed significantly increased expression levels of IL-10 ( Figure 6 , upper panel) and TGF-b ( Figure 6 , middle panel) in recipient mice infused with donor-specific SSCs compared to those in the control mice. In contrast, a significant reduction of IL-2 expression was observed in the splenocytes of recipient mice that received SSCs infusions ( Figure 6, lower panel) .
Infusion of donor type SSC-derived DCs prior to transplantation prolongs cardiac allograft survival Finally, we asked whether DCs derived from SSCs could account for the suppressive properties of SSCs in the context of allograft transplantation. The effect of SSC-derived DCs on the in vivo alloimmune response was determined in a fully histocompatibility complex -mismatched vascularized heart graft model. Donor type SSC-derived DCs (2310 5 ) were infused intravenously 7 days prior to engraftment of a BALB/c donor heart in the abdominal cavity of C57BL/6 recipient mice. This resulted in an increased MST of 12.361.51 days compared to control mice that were infused with PBS alone (MST: 6.960.31 days, P,0.01; Figure 7a ). Histological analysis of these allografts after day 7 of transplantation revealed less allograft infiltration and necrosis in the DC infused recipients than in recipient mice pre-treated with PBS (Figure 7b) .
The in vivo suppressive effect of the SSC-derived DCs might involve the expansion or generation of other types of regulatory DCs and T cells (i.e., Tregs). To address this issue, flow cytometry was performed to phenotype the DCs and T cells in the spleens harvested from recipient mice when the complete cessation of heart graft pulsation was observed. Figure 6 Splenocytes from recipients treated with a SSC infusion exhibit an antiinflammatory cytokine expression profile. Splenocytes were harvested from mice that were treated with SSC infusions or Spls or PBS-treated control mice 7 days after transplantation, and the levels of IL-10, TGF-b and IL-2 were assessed by reverse transcriptase PCR. The bar graphs indicate the expression levels of the cytokines relative to the expression of the housekeeping gene beta-actin. The data shown are representative of three separate experiments. *P,0.05, **P,0.01. N. S., not significant; PBS, phosphate-buffered saline; Spl, spleen cell; SSC, splenic stromal cell; TGF, transforming growth factor.
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Phenotypic differences were detected among the DCs. Splenic DCs from mice infused with SSC-derived DCs exhibited an increase in the expression of CD8a and IL-10 but a decrease in the expression B220 compared with that of control mice infused with PBS alone (Figure 8a and b). These alterations suggest a tolerogenic phenotype of the DCs. Furthermore, the expression of Foxp3 in the CD4 1 T cells of mice infused with SSC-derived DCs was increased (Figure 8c ), whereas the IFN-c production by the CD8 1 T cells was markedly suppressed (Figure 8d ) compared with that of PBS-treated control mice.
DISCUSSION
In the present study, we demonstrated that SSCs exert an immune regulatory function, either through directing the differentiation of DCs into regulatory DC subsets or by augmenting the generation of Tregs. Our data indicate that SSCs not only contain progenitor cells with the capacity to differentiate into DCs with regulatory function, but also establish the immune microenvironment necessary for generation of tolerogenic signals to control the overwhelming alloreactive T-cell response against allografts.
Spleen-derived stromal cells were heterogeneous and composed primarily of fibroblasts, macrophages and endothelial cells. 15 After 7 days of culture, we found that SSCs consisted of macrophages, DCs and other cell types that may have important regulatory functions. Indeed, stromal cells exert immune regulatory effects by producing a variety of cytokines and inhibitory molecules. Endothelial splenic stroma induces hematopoietic stem cells to differentiate into regulatory dendritic cells via the production of IL-10. 22 Human bone marrow stromal cells inhibit in vitro allogeneic T-cell responses by upregulating IDO gene expression. 23 In line with these findings, our data indicate that infusion of animals with donor-derived SSCs prolonged skin allograft survival. There are two possible underlying mechanisms that could be responsible for the regulatory functions of the SSCs. One possibility is that proinflammatory mediators such as INF-c and TNF-a that are produced by alloreactive T cells may trigger SSCs to upregulate the expression of anti-inflammatory cytokines, such as IDO (Figure 2b ), IL-10 and TGF-b (Figure 6 ), which would inhibit alloreactive T cell-mediated responses against the skin allograft. Another possibility is that SSCs could attenuate the proinflammatory reaction toward alloantigens by indirectly inducing the production of regulatory DCs.
Several DC subsets have been reported to promote peripheral tolerance in cases of autoimmunity and alloimmunity. 24, 25 The Figure 7 Intravenous infusion of SSC-derived DCs prolongs the survival of heart allografts and attenuates the infiltrate of leukocytes into the grafts. (a) C57BL/6 mouse recipients were treated with intravenous infusion of either 2310 5 SSC-derived DCs from BALB/c mice per mouse or PBS 7 days prior to transplantation. Subsequently, the mice were transplanted with BALB/c heart grafts (n56-8 mice per group). The MST of the grafts was monitored. **P,0.01. (b). Histological analysis of heart allografts after transplantation revealed a reduced level of allograft leukocytes infiltration and necrosis in the SSC-derived DCs-treated group compared to that in the PBS-treated group (3200). The data shown are representative of three independent experiments. DC, dendritic cell; MST, mean survival time; PBS, phosphatebuffered saline; SSC, splenic stromal cell.
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CD11c
1 CD8a 1 DC subset promotes peripheral self-tolerance through their ability to capture and cross-present tissue-associated antigens to naive cytotoxic T lymphocytes and thus can prolong the survival of heart allografts in rodents. 26, 27 More recently, pDC precursors have been identified and implicated in the induction of allogeneic T-cell hyporesponsiveness. 28, 29 In line with these findings, our phenotypic analysis of splenic DCs in the recipient mice indicated that infusion of SSCs increased the proportion of DC subsets with tolerogenic effects, such as CD11c 1 CD8a 1 DCs and pDCs. Unexpectedly, the difference in the numbers of CD11c 1 CD45RB 1 DCs between the control group (PBS-infused) and the SSC-infused group (Figure 4 , upper panel) was not very significant, possibly because the in vivo cytokine milieu in the alloimmunity setting did not favor the development of CD11c 1 CD45RB 1 DC supported by SSC.
Some regulatory DCs regulate alloantigen-specific T-cell responses by inducing regulatory T cells. 30, 31 When stimulated by allogeneic immature DCs, CD4
1 T cells derived from cord blood can give rise to IL-10-producing Tr1. 32 Similarly, IL-10-secreting CD8 1 Tregs can be generated from naive CD8
1 T cells when stimulated with allogeneic pDCs in vitro. 33 Our previous studies suggest that IDO-expressing DCs may regulate a delicate balance of cytokines that favors the differentiation of naive CD4 1 T cells into Tregs instead of CD4 1 effector T cells. 17, 19 Furthermore, CD4 1 CD25 1 Foxp3 1 Tregs can be expanded from a polyclonal repertoire by allogeneic DCs, and these alloantigenselected Tregs are more effective suppressors of responses to major transplantation antigens. 34 Our data indicated that infusion of donor-derived SSCs enhances the production of CD4
1
CD25
1 Foxp3 1 Tregs associated with the upregulation of TGF-b and IL-10 expression in recipient splenocytes. SSCs likely induce the generation of Tregs by promoting the development of DCs with regulatory functions. These DC subsets favor the development and expansion of Tregs. This idea is further supported by the observation that infusion of the isolated SSC-derived DCs prolongs graft survival in allogeneic heart-transplanted mice.
Previous studies have shown that mesenchymal stem cells (MSCs) exhibit immunomodulatory properties and exhibit the potential to suppress alloreactive T-cell responses. 35, 36 It has been reported that co-infusion of MSCs with unmodified bone marrow limits the toxicity of allogeneic bone marrow transplantation, enhances mixed chimerism and improves vascularized skin graft survival in rats. Secretion of high levels of IL-6, TGF-b1 and hepatocyte growth factor but not IL-10 or IL-4 by MSC could play a role in their anti-inflammatory and immunoregulatory function. 35 Considering that we prepared the stromal cells from spleen but not from bone marrow, MSCs derived from spleen stromal cells could also play a partial role in inhibiting allogeneic T-cell proliferation. Indeed, we observed that IL-10-producing regulatory DCs and/or T cells exhibited the ability to inhibit allogeneic T-cell proliferation and reduce IFN-c secretion, thereby downregulating alloreactive T-cell responses (Figure 8) . Additionally, because the spleen cells we used to serve as a control also contain some stromal cells, we observed that infusion of these spleen cells also promoted skin allograft survival; however, the spleen cells displayed a lower potency than purified SSCs in terms of induction of Tregs, DC subset generation and IL-10 production in an alloimmunity setting.
In conclusion, we have shown that SSCs are able to differentiate into regulatory DCs and that these cells exert a potent inhibition of alloreactive T-cell proliferation and thus promote prolongation of allograft survival. The mechanisms by which donor-derived SSCs regulate the alloimmune setting include the upregulation of IDO expression, promoting the generation of DC subsets with regulatory functions and augmenting the expansion of CD4 1 CD25 1 Foxp3 1 Treg cells. Our data suggest that donor-derived SSCs could serve as an important immune therapeutic target for the induction of antigen-specific tolerance in transplantation.
